News for Nkarta, Inc. (NKTX)

Nkarta's pipeline updates show steady progress, but no major catalysts have emerged. Read what warrants a cautious outlook on NKTX stock now.

On June 10, 2025, analyst Salim Syed from Mizuho issued a report on Nkarta (NKTX) with key updates impacting investors and stakeholders. Mizuho has maintained i

Mizuho has revised its price target for Nkarta (NKTX), reducing it from $16 to $14 while maintaining an Outperform rating. This adjustment follows the company's

Nkarta, trading under the ticker NKTX, has announced that Shawn Rose will become the company's new Chief Medical Officer and Head of Research and Development, e

**media[647717]**

On May 15, 2025, Needham analyst Gil Blum reaffirmed a "Buy" rating for Nkarta (NKTX) while adjusting the price target from $11.00 to $10.00. The revised price

On May 15, 2025, William Blair made a significant change to its stock rating for Nkarta (NKTX). The analyst, Sami Corwin, has downgraded NKTX's rating from

Nkarta Inc. (NKTX) has experienced a downgrade by William Blair, shifting from an "Outperform" to a "Market Perform" rating. The firm has not set a specific pri

Nkarta (NKTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

**media[591526,591527]**

Highly experienced biotech executive and board member will assist Kalaris in achieving its next phase of growth PALO ALTO, Calif., April 04, 2025 (GLOBE NEW

**media[582715]**

Nkarta's NKX019 offers hope for autoimmune treatment. Upcoming trial data and strategic moves could fuel recovery. Read more about NKTX stock here.

New Jersey-based Greenland Acquisition Corp (GTEC) is up over 79 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

Morning Reads

**media[577728]**

The heavy selling pressure might have exhausted for Nkarta (NKTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Nkarta (NKTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. ( NKTX), a biopharmaceutical company developing engineered natural killer (NK) cel